A new species of Bryk, 1949 (Lepidoptera, Erebidae, Herminiinae) from Jiangxi, China.

Background: Bryk, 1949 (Erebidae, Herminiinae) is a medium-sized, frail-bodied genus of moths that externally resembles other genera in the generic complex. All known larvae of this genus feed on fresh leaves of moss. This genus is widely distributed from the Himalayas to Southeast Asia, Japan, Borneo, Sulawesi and New Guinea.

Combined transcriptome and whole genome sequencing analyses reveal candidate drug-resistance genes of .

Avian coccidiosis is a widespread intestinal disease found in poultry that causes substantial economic losses. To extensively investigate the molecular mechanism of drug resistance in , we analyzed the sporozoites and second-generation merozoites of drug-sensitive (DS), diclazuril-resistant (DZR) strain, and salinomycin-resistant (SMR) strains of through transcriptome sequencing. Whole genome sequencing analyses were performed on resistant strains at different concentrations-11 sensitive strains, 16 field diclazuril-resistant strains, and 15 field salinomycin-resistant strains of .

Risk factors of recurrent periprosthetic joint infection of the knee after two-stage reimplantation.

Introduction: Prosthetic joint infection (PJI) is one of the most common and detrimental complications of total knee replacement arthroplasty (TKA). Despite extensive efforts, including two-stage reimplantation, to eradicate PJI, it still recurs in a substantial number of patients. However, the risk factors of recurrence after two-stage reimplantation of the knee have not been established.

Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): multicentre randomised controlled trial.

Objective: To assess whether intra-arterial tenecteplase administered after successful endovascular recanalisation improves outcomes in patients with acute arterial occlusion of the posterior circulation.

Design: Multicentre randomised controlled trial.

Setting: 31 hospitals in China, 24 January 2023 to 24 August 2023.

Efficacy and safety of topical cream containing aminoacryl tRNA synthetase complex interacting 1-derived peptide in mitigating radiation dermatitis after adjuvant radiotherapy for breast cancer.

Purpose: Acute radiation dermatitis (ARD) is a frequent side effect experienced by breast cancer patients undergoing radiotherapy. This study aimed to assess the efficacy and safety of a topical cream containing aminoacryl tRNA synthetase complex interacting 1 (AIMP1)-derived peptide (AdP) in mitigating radiation dermatitis (RD) in breast cancer patients undergoing radiotherapy.

Methods: An 8-week single-center, prospective pilot study was conducted to compare the clinical efficacy and safety of an AdP-containing cream with a control cream lacking AdP for the mitigation of RD.